Search clinical trials for: 99mTc MDP/HDP Bone dosimetry scans and measurements

Total 178 results

Royal Marsden NHS Foundation Trust

Completed

Simplification of Low Level Internal Dosimetry (SOLLID)

Exposure to Medical Diagnostic Radiation

United Kingdom
University Medical Center Groningen

Recruiting

Value of Intense Phenotyping in Heart Failure With Preserved Ejection Fraction (VIP-HF2)

Heart Failure, Diastolic

Netherlands
Mohamed Fathy

Unknown

The Diagnostic Performance of Skeletal 99mTc-MDP SPECT/CT in Patients With Low Back Pain

Low Back Pain, Mechanical
University of Manitoba
Winnipeg Regional Health Authority

Terminated

Sodium Pertechnetate (99Tc) Injection Generator: 99mTc From Neutron-activation 99Mo v 99mTc From Fission 99Mo

Cancer of Bone

Canada
Medhat Osman
Blue Earth Diagnostics

Completed

Prostate Cancer Patients With Biochemical Recurrence

Patients With Prostate Cancer

United States
Molecular Insight Pharmaceuticals, Inc.

Completed

Study to Evaluate 99mTc-MIP-1404 SPECT/CT Imaging in Men With Biopsy Proven Low-Grade Prostate Cancer (proSPECT-AS)

Prostate Cancer

United States, Canada
Universitair Ziekenhuis Brussel

Terminated

Body Composition, Bone Health and Hormonal Status in HIV-1-infected Individuals (BONBO)

HIV-1 | Treatment-naïve

Belgium
Valentina Garibotto
University Hospital, Geneva

Completed

18F-NaF-PET/MR vs 99mTc-MDP-SPECT/CT to Detect Bone Metastases in Prostate Cancer Patients.

Prostate Cancer | Bone Metastases

Switzerland
Xinhua Hospital, Shanghai Jiao Tong University...

Completed

99Tc-MDP in Postmenopausal Women With Differentiated Thyroid Cancer and Osteoporosis

Osteoporosis | Differentiated Thyroid Cancer

China
HTA Co., Ltd.

Completed

Diagnostic Performance and Safety of 18F-NaF-PET/CT in Bone Metastases Compared With 99mTc⁃MDP-BS±SPECT

Bone Metastases

China
Clinique Bizet

Completed

Evaluation and Comparison of Two Biomarkers (VOP and SCC) for the Prognosis of the Occurrence of Clinical Cardiovascular Events (VOP-SCC)

Cardiovascular Risk Factor

France
Stanford University

Completed

Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases

Cancer

United States
Turku University Hospital
University of Turku

Completed

Novel Imaging in Staging of Primary Prostate Cancer (PROSTAGE)

High Risk Prostate Cancer

Finland
American College of Radiology - Image Metrix
World Molecular Imaging Society

Unknown

F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets

Bone Metastases

United States, Australia, Austria, Portugal, Switzerland
University of California, San Francisco
Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma

Not yet recruiting

Efficacy of Ra-223 in PSMA PET Optimally Selected Patients

Castration-Resistant Prostate Carcinoma | Metastatic Malignant Neoplasm in the Bone | Stage IVB Prostate Cancer AJCC v8

United States
Arkansas Children's Hospital Research Institute
University of Arkansas

Unknown

Effects of Swallowed Steroids on Bone Density and Growth in Pediatric Eosinophilic Esophagitis

Eosinophilic Esophagitis

United States
National Cancer Institute (NCI)

Completed

Whole Body Fluorine F 18 Sodium Fluoride PET/CT Scan and Whole Body MRI in Finding Bone Metastases in Patients With Prostate Cancer

Recurrent Prostate Cancer | Bone Metastases | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
Medical University of South Carolina
National Institute on Minority Health and Health Disparities (NIMHD); Ralph...

Completed

Vitamin D Supplementation in RNA-seq Profiles of Single-core Prostate Samples, Among Veterans (VitD/RNA-seq)

Vitamin D Deficiency | Prostate Cancer | Stress Reaction

United States
Xinhua Hospital, Shanghai Jiao Tong University...

Recruiting

99Tc-MDP Treatment for Knee Osteoarthritis

Treatment Outcome

China
Ottawa Hospital Research Institute
Canadian Breast Cancer Foundation

Completed

The ODYSSEY TRIAL Phase IV Trial Evaluating the Palliative Benefit of Pamidronate or Zoledronic Acid in Breast Cancer (ER11-03)

Breast Cancer

Canada
Dana-Farber Cancer Institute
AstraZeneca; Cyclacel Pharmaceuticals, Inc.

Active, not recruiting

Olaparib + Sapacitabine in BRCA Mutant Breast Cancer

Breast Cancer

United States
National Cancer Institute (NCI)

Recruiting

Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes

Stage III Bladder Cancer AJCC v8 | Stage IV Bladder Cancer AJCC v8 | Metastatic Bladder Carcinoma | Advanced Bladder Carcinoma | Advanced Genitourinary System Carcinoma | Metastatic Genitourinary System Carcinoma

United States
National Cancer Institute (NCI)

Suspended

Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors

Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Refractory Cholangiocarcinoma

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

Endometrial Mixed Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Stage IV Uterine Corpus Cancer AJCC v8 | Endometrial Adenocarcinoma | Endometrioid Adenocarcinoma

United States, Canada
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer

Stage III Colon Cancer AJCC v8 | Colon Adenocarcinoma | Microsatellite Stable Colon Carcinoma | Stage IIB Colon Cancer AJCC v8 | Stage IIC Colon Cancer AJCC v8

United States
Eben Rosenthal
National Cancer Institute (NCI)

Completed

Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastatic Lymph Nodes in Patients With Head&Neck Cancer

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Squamous Cell Carcinoma of the Head and Neck (SCCHN)

United States
The University of Texas Health Science Center at...
Sangi Co., Ltd.

Completed

Clinical Efficacy in Relieving Dentin Hypersensitivity of Nanohydroxyapatite-Containing Toothpastes and Cream

Dentin Sensitivity

United States
British Columbia Cancer Agency
Canadian Institutes of Health Research (CIHR)

Completed

18F-NaF PET Imaging for Bone Scintigraphy

Bone Metastases From Breast or Prostate Cancer

Canada
National Cancer Institute (NCI)

Recruiting

Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

HIV Infection | Advanced Malignant Solid Neoplasm | Kaposi Sarcoma | Lung Carcinoma | Metastatic Malignant Solid Neoplasm | Unresectable Solid Neoplasm | Anal Carcinoma | Recurrent Classic Hodgkin Lymphoma | Refractory Classic Hodgkin Lymphoma

United States, Australia
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Carcinoma

United States, Puerto Rico
National Cancer Institute (NCI)

Active, not recruiting

Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Unresectable Breast Carcinoma | Metastatic Breast Carcinoma | Locally Advanced Breast Carcinoma | Metastatic HER2-Negative Breast Carcinoma | Unresectable HER2-Negative Breast Carcinoma | Locally Advanced HER2-Negative...

United States
Sichuan University

Recruiting

Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC

Lung Cancer | Extensive-stage Small-cell Lung Cancer

China
Fundación Pública Andaluza para la gestión de la...

Unknown

Prevalence of Amyloidosis in Heart Failure (PREVAMIC) (PREVAMIC)

Heart Failure

Spain
National Cancer Institute (NCI)

Withdrawn

Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment Trial

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic HER2-Negative Breast Carcinoma | Unresectable HER2-Negative Breast Carcinoma
National Cancer Institute (NCI)

Recruiting

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Stage IV Renal Cell Cancer AJCC v8 | Sarcomatoid Renal Cell Carcinoma | Stage IV Bladder Cancer AJCC v8 | Stage IV Urethral Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Bladder Adenocarcinoma | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Collecting Duct Carcinoma | Bladder... and other conditions

United States, Puerto Rico
Eisai Inc.

Terminated

Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma

Unresectable Stage III Melanoma | Wild Type BRAF Stage IV Melanoma

United States
Eisai Inc.

Completed

Study of Poly (ADP-Ribose) Polymerase (PARP) Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors

Solid Tumors

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Sarcomatoid Renal Cell Carcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation

Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome | Acute Myeloid Leukemia Post Cytotoxic Therapy

United States
Osel, Inc.
National Cancer Institute (NCI); City of Hope Medical Center; Miyarisan Pharmaceuticals...

Recruiting

CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer

Metastatic Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Sarcomatoid Renal Cell Carcinoma | Advanced Renal Cell Carcinoma | Advanced Sarcomatoid Renal...

United States
National Cancer Institute (NCI)

Recruiting

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder for Bladder Cancer Treatment, MODERN Study

Stage III Bladder Urothelial Carcinoma AJCC v6 and v7 | Stage IV Bladder Urothelial Carcinoma AJCC v7 | Stage II Bladder Urothelial Carcinoma AJCC v6 and v7 | Muscle Invasive Bladder Urothelial Carcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer

Malignant Solid Neoplasm | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Invasive Breast Carcinoma | Breast Adenocarcinoma

United States
National Cancer Institute (NCI)

Suspended

Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working

Locally Advanced Uterine Corpus Leiomyosarcoma | Metastatic Uterine Corpus Leiomyosarcoma | Stage III Uterine Corpus Leiomyosarcoma AJCC v8 | Stage IV Uterine Corpus Leiomyosarcoma AJCC v8 | Unresectable Uterine Corpus Leiomyosarcoma

United States, Puerto Rico
Dalian University

Completed

99Tc-MDP for Thyroid-Associated Ophthalmopathy

Thyroid-Associated Ophthalmopathy

China
Shanghai Gynecologic Oncology Group
Fudan University

Not yet recruiting

Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma

China
National Cancer Institute (NCI)

Recruiting

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Advanced Pancreatic Carcinoma | Metastatic Pancreatic Carcinoma | Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Castration-Resistant Prostate Carcinoma and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

Ovarian Endometrioid Adenocarcinoma | Fallopian Tube Carcinoma | Triple-Negative Breast Carcinoma | Ovarian Serous Adenocarcinoma | Primary Peritoneal Serous Adenocarcinoma | Ovarian High Grade Serous Adenocarcinoma | Ovarian Serous Surface Papillary Adenocarcinoma

United States
European Organisation for Research and Treatment...

Active, not recruiting

Biomarker-based Study in R/M SCCHN (UPSTREAM)

Carcinoma, Squamous Cell of Head and Neck

France, Spain, Belgium, Italy, United Kingdom
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Lung Non-Small Cell Squamous Carcinoma | Recurrent Lung Non-Small Cell Carcinoma | Deleterious BRCA1 Gene Mutation | Deleterious BRCA2 Gene Mutation | Recurrent Lung Adenocarcinoma | Loss of Heterozygosity | Recurrent... and other conditions

United States
National Cancer Institute (NCI)

Recruiting

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

Pancreatic Acinar Cell Carcinoma | Pancreatic Adenosquamous Carcinoma | Pancreatic Squamous Cell Carcinoma | Resectable Pancreatic Acinar Cell Carcinoma | Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Adenosquamous Carcinoma | Resectable Pancreatic Carcinoma

United States

Search clinical trials for: 99mTc MDP/HDP Bone dosimetry scans and measurements

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Singapore

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations